Pipeline
Novel biologics portfolio & partnerships
Obecnie pracujemy nad szeregiem projektów, z których najbardziej zaawansowany obejmuje rozwój humanizowanego antagonisty receptora CD89. Celem JJP Biologics jest doprowadzenie naszych projektów do etapu, na którym ich skuteczność potwierdzona zostanie w badaniach klinicznych. Partnerstwo w rozwoju projektów leków biologicznych jest jednym z modeli współpracy JJP Biologics z innymi firmami. Aby dowiedzieć się więcej, zapraszamy do kontaktu.
Humanizowany antagonista anty-CD89
Auto-antigen specific IgA antibodies are associated with disease severity in over a dozen of different auto-immune indications and therefore disease-specific IgA antibodies were selected as companion diagnostic for the development of an innovative therapeutic.
Nowatorskie podejście do roli neutrofili w patogenezie chorób autoimmunologicznych
The anti-CD89 (FcαRI) program focuses on antagonizing the IgA receptor CD89 for the treatment of IgA-mediated diseases and the prevention of IgA-mediated pathogenic neutrophilic tissue damage. Neutrophils are part of the innate immune system and are the most ignored cell type of the immune system, but play a devastating role in many auto-immune diseases. Our novel approach is unique in both its target and in its therapeutic potential for neutrophilic-driven diseases, in which treatment options are severely lacking. A significant proportion of auto-immune patients who are not responding to TNF inhibitors have high neutrophil involvement in the disease accompanied by high auto-antigen specific IgA responses. Beyond neutrophil CD89 is also expressed on monocytes, macrophages and eosino-phils which upon IgA binding contribute to the inflammatory response that can also be inhibited by the antagonist anti-CD89 antibody.
The candidate antibodies being developed by JJP Biologics can prevent the IgA-mediated activation of the immune system and inhibit the release of chemo-attractive signals and pathogenic molecules, making them unique in their class. Furthermore, as companion diagnostic for patient stratification and personalized medicine, auto-antigen IgA antibodies which in most auto-immune disease are already embedded in daily clinical diagnosis of patients.
Okazuje się, że u znacznej części pacjentów cierpiących na schorzenia autoimmunologiczne, nie reagujących na inhibitory TNF, neutrofile odgrywają istotną rolę w przebiegu choroby. Reakcjom tym towarzyszą wysokie poziomy przeciwciał klasy IgA specyficznych dla autoantygenów. Przeciwciało będące antagonistą CD89, opracowywane przez JJP Biologics, zapobiega aktywacji układu odpornościowego związanej z IgA oraz hamuje uwalnianie prozapalnych czynników chemotaktycznych. Mechanizm ten czyni je zdecydowanie wyjątkowym produktem w segmencie terapeutycznych przeciwciał monoklonalnych. Warto zwrócić uwagę również na to, że diagnostyka towarzysząca związana z identyfikacją IgA specyficznych dla autoantygenów już teraz stanowi element codziennej diagnostyki klinicznej pacjentów. Podmioty zainteresowane kupnem licencji na wytwarzanie terapeutycznego przeciwciała monoklonalnego o działaniu antagonistycznym w stosunku do CD89 zapraszamy do kontaktu.
Undisclosed immuno-oncology antibody
The level of PD-L1 expression on tumours is being used as companion diagnostic to select patients for the treatment with the highly successful anti-PD1 antibodies. In analogy with the PD-L1-PD1 axis, we have selected another checkpoint inhibitor receptor expressed on various tumours and for which the level of expression highly correlates to poor prognosis and therefore is selected to serve as companion diagnostic for the current program.
Nowatorskie podejście do roli neutrofili w patogenezie chorób autoimmunologicznych
Our validated expertise in immunotherapy prompted the discovery and generation of innovative antibodies to new checkpoint inhibitor targets. This target was selected because of its high tumour expression, accompanied by a poor prognosis and immune suppressive tumour microenvironment. Similar to the PD1-PD-L1 axis, tumour expression of our novel target can be used as companion diagnostic for a personalized medicine strategy. This highly selective molecule blocks the regulatory interactions of the target with the patient’s immune system, while leaving Its stimulatory capacity untouched.
Pipeline
We also have a range of other undisclosed biologics in development.
Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution
High IgA responses to the virus in severe patients and affinity matured IgG antibodies in mild patients. The viral surface…
IgA mediated pathology after COVID-19
Another example of IgA mediated pathology after COVID-19 infection. Hopefully for the patient this was a transient increase in specific…
High S1-specific IgA antibody levels discriminate severely ill SARS-CoV-2 patients
High S1-specific IgA antibody levels discriminate severely ill SARS-CoV-2 patients. The virus acts as high avidity matrix for neutrophils to…
Subskrybuj
Subskrybuj
Otrzymuj najświeższe informacje
Some description text for this item